Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot73410.32687/0869-866X-2021-29-s2-1287-1291Научная статьяQUANTITATIVE AND QUALITATIVE CHARACTERISTICS OF THE POPULATION OF PATIENTS WITH LIVER CIRRHOSIS IN MOSCOWKornilovaE. B.-ZavyalovA. A.-Hołownia-VoloskovaM. E.-Ar’kovaE. S.-TolkushinA. G.-Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare DepartmentDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw1512202129S21287129123112021Copyright © 2021,2021Introduction. Liver cirrhosis is a major but preventable cause of health loss worldwide. The era of «big data» allows us to evaluate this nosology in a new format.Purpose. Evaluation of the registered population of patients with cirrhosis of the liver of cirrhosis of various etiology in Moscow. Moscow.Materials and methods. Based on the data of the Moscow Department of Healthcare for the drug provision for the period from 2017 to 2019. Тhe population of patients with an established diagnosis of liver (other etiology) was characterized according to ICD-10 code K.74 (K74.0-74.6) according to the International Statistical Classification of Diseases and Related Health Problems of the 10th revision.Results. Over a 4-year period, more than 2 thousand patients with established diagnosis of liver cirrhosis received preferential drug provision in Moscow. The largest part of the population of patients with liver cirrhosis receiving preferential drug provision in Moscow is represented by the patients of age groups 40-59 years old and 60-79 years old, the groups 30-39 years old and 80-99 years old were comparable annually. There was a decrease in the number of patients with liver cirrhosis in the age groups of 30-39 and 18-19 years compared with the base year (2017) by 37% and 57%, respectively. At the same time, in pediatric patients (from the neonatal period to 17 years), there was an intensive increase in patients from 52 to 550% compared to the baseline year (2017).COVID-19liver cirrhosischronic hepatitishepatocellular carcinomadrug provisionoutcomes researchburden of diseaseliver transplantationCOVID-19цирроз печенихронический гепатитгепатоцеллюлярная карциномальготное лекарственное обеспечениеоценка исходовбремя болезнитрансплантация печени[Roth G. A., Abate D., Abate K. H. et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017 // Lancet. 2018. Vol. 392, N 10159. P. 1736-1788.][Pinzani M., Rosselli M., Zuckermann M. Liver cirrhosis // Best Pract. Res. Clin. Gastroenterol. 2011. Vol. 25, N 2. P. 281-290. DOI: 10.1016/j.bpg.2011.02.009.][Ярошенко Е. Б. Сравнительная клиническая характеристика цирроза печени различной этиологии: дис. … канд. мед. наук. М., 2010. 121 с.][Armstrong G. L., Alter M. J., McQuillan G. M., Margolis H. S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States // Hepatology. 2000. Vol. 31, N 3. P. 777-782. DOI: 10.1002/hep.510310332.][D’Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies // J. Hepatol. 2006. Vol. 44, N 1. P. 217-231. DOI: 10.1016/j.jhep.2005.10.013][GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 // Lancet Gastroenterol. Hepatol. 2020. Vol. 5, N 3. P. 245-266. DOI: 10.1016/S2468-1253(19)30349-8.][Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low and middle-income countries. Global progress report 2020. Geneva: World Health Organization, 2021.][Blach S., Kondili L. A., Aghemo A. et al. Impact of COVID-19 on global HCV elimination efforts // J. Hepatol. 2021. Vol. 74, N 1. P. 31-36. DOI: 10.1016/j.jhep.2020.07.042.][World Health Organization. The world health report 2003: Shaping the future. Geneva: World Health Organization, 2003.][Asrani S. K., Devarbhavi H., Eaton J., Kamath P. S. Burden of liver diseases in the world // J. Hepatol. 2019. Vol. 70, N 1. P. 151-171. DOI: 10.1016/j.jhep.2018.09.014.][Александрова Г. А., Голубев Н. А., Тюрина Е. М. и др. Сборник статистических материалов «Заболеваемость всего населения России в 2019 году с диагнозом, установленным впервые в жизни». М., 2020. 140 с.][Pimpin L., Cortez-Pinto H., Negro F. et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies // J. Hepatol. 2018. Vol. 69, N 3. P. 718-735. DOI: 10.1016/j.jhep.2018.05.011][Yatsuhashi H., Sano H., Hirano T., Shibasaki Y. Real-world hospital mortality of liver cirrhosis inpatients in Japan: a large-scale cohort study using a medical claims database: Prognosis of liver cirrhosis // Hepatol. Res. 2021. Vol. 51, N 6. P. 682-693. DOI: 10.1111/hepr.13635.][Аксенова Е. И. Влияние новых медицинских технологий на качество медицинской помощи в мегаполисах (на примере города Москвы) // Здоровье мегаполиса. 2020. Т. 1, № 1. С. 8-14.][Каганов Б. С., Зайнудинов З. М., Строкова Т. В. и др. Критерии диагностики и клиническое течение цирроза печени у детей // Инфекционные болезни. 2008. Т. 6, № 3. С. 14-21.][Четкина Т. С., Потапов А. С., Цирульникова О. М. Болезнь Вильсона у детей: варианты манифестации и трудности ранней диагностики // Вопросы диагностики в педиатрии. 2011. Т. 3, № 1. С. 41-47.]